These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20357366)

  • 1. PYY3-36 and oxyntomodulin can be additive in their effect on food intake in overweight and obese humans.
    Field BC; Wren AM; Peters V; Baynes KC; Martin NM; Patterson M; Alsaraf S; Amber V; Wynne K; Ghatei MA; Bloom SR
    Diabetes; 2010 Jul; 59(7):1635-9. PubMed ID: 20357366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively.
    Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR
    Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men.
    Schmidt JB; Gregersen NT; Pedersen SD; Arentoft JL; Ritz C; Schwartz TW; Holst JJ; Astrup A; Sjödin A
    Am J Physiol Endocrinol Metab; 2014 Jun; 306(11):E1248-56. PubMed ID: 24735885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-administration of SR141716 with peptide YY3-36 or oxyntomodulin has additive effects on food intake in mice.
    White NE; Dhillo WS; Liu YL; Small CJ; Kennett GA; Gardiner JV; Ghatei MA; Bloom SR
    Diabetes Obes Metab; 2008 Feb; 10(2):167-70. PubMed ID: 17941865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers.
    Tan T; Behary P; Tharakan G; Minnion J; Al-Najim W; Albrechtsen NJW; Holst JJ; Bloom SR
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2364-2372. PubMed ID: 28379519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined GLP-1, Oxyntomodulin, and Peptide YY Improves Body Weight and Glycemia in Obesity and Prediabetes/Type 2 Diabetes: A Randomized, Single-Blinded, Placebo-Controlled Study.
    Behary P; Tharakan G; Alexiadou K; Johnson N; Wewer Albrechtsen NJ; Kenkre J; Cuenco J; Hope D; Anyiam O; Choudhury S; Alessimii H; Poddar A; Minnion J; Doyle C; Frost G; Le Roux C; Purkayastha S; Moorthy K; Dhillo W; Holst JJ; Ahmed AR; Prevost AT; Bloom SR; Tan TM
    Diabetes Care; 2019 Aug; 42(8):1446-1453. PubMed ID: 31177183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gut hormones as peripheral anti obesity targets.
    Small CJ; Bloom SR
    Curr Drug Targets CNS Neurol Disord; 2004 Oct; 3(5):379-88. PubMed ID: 15544446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Drewe J; Beglinger C
    Am J Clin Nutr; 2010 Oct; 92(4):810-7. PubMed ID: 20720259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males.
    Sloth B; Davidsen L; Holst JJ; Flint A; Astrup A
    Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E604-9. PubMed ID: 17566112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of oxyntomodulin and peptide tyrosine-tyrosine (PYY) in appetite control.
    Wynne K; Bloom SR
    Nat Clin Pract Endocrinol Metab; 2006 Nov; 2(11):612-20. PubMed ID: 17082808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study.
    Bergmann NC; Lund A; Gasbjerg LS; Meessen ECE; Andersen MM; Bergmann S; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Knop FK
    Diabetologia; 2019 Apr; 62(4):665-675. PubMed ID: 30683945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide YY and glucagon-like peptide-1 contribute to decreased food intake after Roux-en-Y gastric bypass surgery.
    Svane MS; Jørgensen NB; Bojsen-Møller KN; Dirksen C; Nielsen S; Kristiansen VB; Toräng S; Wewer Albrechtsen NJ; Rehfeld JF; Hartmann B; Madsbad S; Holst JJ
    Int J Obes (Lond); 2016 Nov; 40(11):1699-1706. PubMed ID: 27434221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure.
    Bagger JI; Holst JJ; Hartmann B; Andersen B; Knop FK; Vilsbøll T
    J Clin Endocrinol Metab; 2015 Dec; 100(12):4541-52. PubMed ID: 26445112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of acclimatisation and habituation to experimental conditions when investigating the anorectic effects of gastrointestinal hormones in the rat.
    Abbott CR; Small CJ; Sajedi A; Smith KL; Parkinson JR; Broadhead LL; Ghatei MA; Bloom SR
    Int J Obes (Lond); 2006 Feb; 30(2):288-92. PubMed ID: 16231018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mycoprotein reduces energy intake and postprandial insulin release without altering glucagon-like peptide-1 and peptide tyrosine-tyrosine concentrations in healthy overweight and obese adults: a randomised-controlled trial.
    Bottin JH; Swann JR; Cropp E; Chambers ES; Ford HE; Ghatei MA; Frost GS
    Br J Nutr; 2016 Jul; 116(2):360-74. PubMed ID: 27198187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The gut hormones PYY 3-36 and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite centers in humans.
    De Silva A; Salem V; Long CJ; Makwana A; Newbould RD; Rabiner EA; Ghatei MA; Bloom SR; Matthews PM; Beaver JD; Dhillo WS
    Cell Metab; 2011 Nov; 14(5):700-6. PubMed ID: 22000927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
    Baggio LL; Huang Q; Brown TJ; Drucker DJ
    Gastroenterology; 2004 Aug; 127(2):546-58. PubMed ID: 15300587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
    Näslund E; Barkeling B; King N; Gutniak M; Blundell JE; Holst JJ; Rössner S; Hellström PM
    Int J Obes Relat Metab Disord; 1999 Mar; 23(3):304-11. PubMed ID: 10193877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermittent intraperitoneal infusion of peptide YY(3-36) reduces daily food intake and adiposity in obese rats.
    Chelikani PK; Haver AC; Reidelberger RD
    Am J Physiol Regul Integr Comp Physiol; 2007 Jul; 293(1):R39-46. PubMed ID: 17428898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of peptide YY in appetite regulation and obesity.
    Karra E; Chandarana K; Batterham RL
    J Physiol; 2009 Jan; 587(1):19-25. PubMed ID: 19064614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.